RhumbLine Advisers’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $267K | Buy |
84,759
+21,617
| +34% | +$68.1K | ﹤0.01% | 3066 |
|
|
2025
Q1 | $198K | Buy |
63,142
+9,970
| +19% | +$31.3K | ﹤0.01% | 3106 |
|
|
2024
Q4 | $231K | Buy |
53,172
+10,290
| +24% | +$44.7K | ﹤0.01% | 3116 |
|
|
2024
Q3 | $114K | Sell |
42,882
-3,111
| -7% | -$8.31K | ﹤0.01% | 3463 |
|
|
2024
Q2 | $102K | Buy |
+45,993
| New | +$102K | ﹤0.01% | 3513 |
|
|
2022
Q2 | – | Sell |
-46,290
| Closed | -$115K | – | 3121 |
|
|
2022
Q1 | $115K | Sell |
46,290
-294
| -0.6% | -$730 | ﹤0.01% | 2861 |
|
|
2021
Q4 | $280K | Sell |
46,584
-1,066
| -2% | -$6.41K | ﹤0.01% | 2726 |
|
|
2021
Q3 | $317K | Buy |
47,650
+1,960
| +4% | +$13K | ﹤0.01% | 2744 |
|
|
2021
Q2 | $304K | Buy |
+45,690
| New | +$304K | ﹤0.01% | 2782 |
|
|
2017
Q2 | – | Sell |
-516
| Closed | -$43K | – | 2929 |
|
|
2017
Q1 | $43K | Buy |
516
+170
| +49% | +$14.2K | ﹤0.01% | 2827 |
|
|
2016
Q4 | $52K | Sell |
346
-207
| -37% | -$31.1K | ﹤0.01% | 2826 |
|
|
2016
Q3 | $179K | Buy |
553
+9
| +2% | +$2.91K | ﹤0.01% | 2710 |
|
|
2016
Q2 | $177K | Buy |
544
+153
| +39% | +$49.8K | ﹤0.01% | 2800 |
|
|
2016
Q1 | $131K | Buy |
391
+14
| +4% | +$4.69K | ﹤0.01% | 2845 |
|
|
2015
Q4 | $147K | Buy |
377
+59
| +19% | +$23K | ﹤0.01% | 2883 |
|
|
2015
Q3 | $130K | Buy |
318
+36
| +13% | +$14.7K | ﹤0.01% | 2901 |
|
|
2015
Q2 | $206K | Buy |
+282
| New | +$206K | ﹤0.01% | 2875 |
|